Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting
Christine Kay, MD, to present 4-year long-term follow-up data from the RESTORE Phase 2b/3 trial in retinitis pigmentosa patients DALLAS, Sept. 15, 2026 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic...
Covered in this story
What has happened since
- Moody's Corporation is up 1.8% since this was published, 35 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Moody's Corporation
- Jefferies: $484 → $560 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MCO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Moody's Corporation →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.